CNXU Overview

Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Wall Street analysts forecast CNXU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNXU is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Conexeu Sciences Inc revenue for the last quarter amounts to NaN USD, decreased

Conexeu Sciences Inc. EPS for the last quarter amounts to USD, decreased

Conexeu Sciences Inc (CNXU) has 0 emplpoyees as of June 13 2026.

Today CNXU has the market capitalization of 285.30M USD.